AAAAAA

   
Results: 1-7 |
Results: 7
Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies including Therapeutic Trials (ESCISIT)
Authors: Swaak, AJG van de Brink, H Smeenk, RJT Manger, K Kalden, JR Tosi, S Marchesoni, A Domljan, Z Rozman, B Logar, D Pokorny, G Kovacs, L Kovacs, A Vlachoyiannopoulos, PG Moutsopoulos, HM Chwalinska-Sadowska, H Dratwianka, B Kiss, E Cikes, N Anic, B Schneider, M Fischer, R Bombardieri, S Mosca, M Graninger, W Smolen, JS
Citation: Ajg. Swaak et al., Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies including Therapeutic Trials (ESCISIT), RHEUMATOLOG, 40(1), 2001, pp. 89-94
Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation
Authors: Swaak, AJG van den Brink, HG Smeenk, RJT Manger, K Kalden, JR Tosi, S Domljan, Z Rozman, B Logar, D Pokorny, G Kovacs, L Kovacs, A Vlachoyiannopoulos, PG Moutsopoulos, HM Chwalinska-Sadowska, H Kiss, E Cikes, N Anic, B Schneider, M Fischer, R Bombardieri, S Mosca, M Graninger, W Smolen, JS
Citation: Ajg. Swaak et al., Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation, LUPUS, 10(1), 2001, pp. 51-58
Antinuclear antibodies: cause of disease or caused by disease?
Authors: Smeenk, RJT
Citation: Rjt. Smeenk, Antinuclear antibodies: cause of disease or caused by disease?, RHEUMATOLOG, 39(6), 2000, pp. 581-584
Histone-containing immune complexes are to a large extent responsible for anti-dsDNA reactivity in the Farr assay of active SLE patients
Authors: Hylkema, MN van Bruggen, MCJ ten Hove, T de Jong, J Swaak, AJG Berden, JHM Smeenk, RJT
Citation: Mn. Hylkema et al., Histone-containing immune complexes are to a large extent responsible for anti-dsDNA reactivity in the Farr assay of active SLE patients, J AUTOIMMUN, 14(2), 2000, pp. 159-168
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha - Findings in open-label and randomized placebo-controlled trials
Authors: Charles, PJ Smeenk, RJT De Jong, J Feldmann, M Maini, RN
Citation: Pj. Charles et al., Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha - Findings in open-label and randomized placebo-controlled trials, ARTH RHEUM, 43(11), 2000, pp. 2383-2390
Systemic lupus erythematosus: clinical features in patients with a diseaseduration of over 10 years, first evaluation
Authors: Swaak, AJG van den Brink, HG Smeenk, RJT Manger, K Kalden, JR Tosi, S Marchesoni, A Domljan, Z Rozman, B Logar, D Pokorny, G Kovacs, L Kovacs, A Vlachoyiannopoulos, PG Moutsopoulos, HM Chwalinska-Sadowska, H Dratwianka, B Kiss, E Cikes, N Branimir, A Schneider, M Fischer, R Bombardieri, S Mosca, M Graninger, W Smolen, JS
Citation: Ajg. Swaak et al., Systemic lupus erythematosus: clinical features in patients with a diseaseduration of over 10 years, first evaluation, RHEUMATOLOG, 38(10), 1999, pp. 953-958
Patients with systemic lupus erythematosus with high plasma levels of sFasrisk relapse
Authors: van Lopik, T Bijl, M Hart, M Boeije, L Gesner, T Creasy, AA Kallenberg, CGM Aarden, LA Smeenk, RJT Smeenk, JT
Citation: T. Van Lopik et al., Patients with systemic lupus erythematosus with high plasma levels of sFasrisk relapse, J RHEUMATOL, 26(1), 1999, pp. 60-67
Risultati: 1-7 |